Berenberg raised the firm’s price target on AbbVie (ABBV) to $275 from $270 and keeps a Buy rating on the shares. The firm upped its forecasts for AbbVie’s Skyrizi and Rinvoq citing an “exceptional” growth outlook.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV:
- Looking for Exposure to Johnson & Johnson Stock (JNJ) ahead of Q4 Earnings? Here’s How to Buy Without the Risk
- AbbVie announces results for epcoritamab from Phase 3 EPCORE DLBCL-1 trial
- Genmab says OS in Phase 3 trial did not reach statistical significance
- Midday Fly By: PNC reports Q4 beat, Regions reports quarterly miss
- AbbVie Expands Oncology Pipeline With First-in-Human ABBV-711 Trial in Advanced Squamous Tumors